Topic 428 - NCI sbir transition to phase II solicitation FY 2023
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91023C00022
- Awardee
-
Earlydiagnostics Inc. UEI SGJ1NZDE89G4
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,994,911
Award facts
- Opportunity
-
- BAA75N91022R00027 Solicitation number
- Contract value 100% obligated
- $1,994,911.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Los Angeles, CA 90095, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Vendor Address Change | $0 | |
| Original award | $1,994,911 |
About this award
This is a $1,994,911.00 firm fixed price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Earlydiagnostics Inc., doing business as Earlydx. The contract was awarded under the NCI SBIR Transition to Phase II Solicitation for fiscal year 2023 and has a total small business set-aside designation.
Earlydx, a for-profit organization, will provide research and development services to support the development of a cloud-based liquid-biopsy platform for the Cancer Research Data Commons. This contract builds on Earlydx's prior work with NCI, including research grants to optimize a blood-based methylation profiling test called MethylScan for early cancer detection, particularly for liver and lung cancer.
Quick answers
Who was awarded contract 75N91023C00022?
75N91023C00022 was awarded to Earlydiagnostics Inc. by National Cancer Institute (National Institutes of Health) on August 15, 2023.
How much is contract 75N91023C00022 worth?
The government has obligated $1,994,911 on 75N91023C00022.
Was contract 75N91023C00022 competed?
The extent of competition for 75N91023C00022 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award